ETG Lublin
- Address
- Ul. Wladyslawa Kunickiego 26a, 20-412 Lublin, Poland
Immune System Diseases and Immune System Phenomena
At ETG Lublin, clinical research is focused on immune-related conditions, with a strong emphasis on understanding how the immune system contributes to disease symptoms and treatment response. The main condition studied is Sjögren’s Syndrome With Moderate-toSevere Symptom State, where trials are exploring whether new approaches can improve patient-reported symptoms and overall disease control.
- Research on Sjögren’s Syndrome and related immune system disorders
- Studies examining immune system processes involved in symptom burden
- Trials evaluating a potential new therapy for symptom relief and treatment benefit
The site’s work in immunology reflects a patient-centered effort to better understand moderate-to-severe autoimmune symptoms and assess whether emerging treatments can make a meaningful difference.
Sjögren’s Syndrome Research
Clinical trials at this health care site in Lublin, Poland are centered on Sjögren’s Syndrome, a condition that can cause significant discomfort and ongoing quality-of-life challenges. The research is designed to evaluate treatment effectiveness and safety while focusing on the symptoms that matter most to patients.
- Studies in autoimmune disease care
- Investigation of patient-reported symptoms in moderate-to-severe disease
- Assessment of a new therapy intended to improve clinical outcomes
With 15 investigators involved across 2 clinical trials, ETG Lublin contributes to focused research on improving how Sjögren’s Syndrome is managed in everyday practice.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 57 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 57 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
- 1H. Lundbeck A/S2active
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ETG Lublin
lock Showing 1 of 36 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-88545223 in Participants with Active Psoriatic Arthritis | Janssen Cilag International | Phase II | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 57 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins | 2 | Unknown | 2025-10-06 | 2025-10-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.